Treats Human Immunodeficiency Virus (HIV-1) infection. ANDA 77268, held by Aurobindo Pharma. Zidovudine.
As of Nov 21, 2026, ANDA 77268 (Zidovudine), held by Aurobindo Pharma, was first approved by FDA on Sep 19, 2005, with 13 approved supplements and 0 published complete response letters.
Zidovudine oral solution is a nucleoside analogue reverse transcriptase inhibitor indicated for: Treatment of Human Immunodeficiency Virus (HIV-1) infection in combination with other antiretroviral agents. Prevention of maternal-fetal HIV-1 transmission. 1.1 Treatment of HIV-1 Zidovudine oral solution, a nucleoside reverse transcriptase inhibitor, is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection. 1.2 Prevention of Maternal-Fetal HIV-1 Transmission Zidovudine oral solution is indicated for the prevention of maternal-fetal HIV-1 transmission.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 19, 2005 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Zidovudine50MG/5ML · solution;oral | Zidovudine | Rx |
| Dec 9, 2020 | Supplement 19Labeling · Standard review | Approved | None posted |
| Jun 11, 2020 | Supplement 18Labeling · Standard review | Approved | None posted |
| Jun 11, 2020 | Supplement 16Labeling · Standard review | Approved | None posted |
| Jun 11, 2020 | Supplement 15Labeling · Standard review | Approved | None posted |
| Jun 11, 2020 | Supplement 14Labeling · Standard review | Approved | None posted |
| Dec 11, 2015 | Supplement 12Manufacturing | Approved | None posted |
| Oct 30, 2012 | Supplement 8Labeling · Standard review | Approved | None posted |
| Mar 6, 2012 | Supplement 7Labeling | Approved | None posted |
| Dec 30, 2011 | Supplement 6Labeling | Approved | None posted |
| Nov 4, 2010 | Supplement 5Labeling | Approved | None posted |
| Jun 14, 2010 | Supplement 4Labeling | Approved | None posted |
| May 13, 2009 | Supplement 3Labeling | Approved | None posted |
| Jun 9, 2008 | Supplement 2Labeling | Approved | None posted |
| Sep 19, 2005 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters